News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN™ ) in Crohn's Disease
Company Also Reports Significant Progress in Advancing Second-Generation CCR9 Drug towards Clinic
View HTML
Toggle Summary ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 Drug Represents Potential New Approach for the Treatment of Inflammatory Disease
Milestone Triggers $10 Million Payment from Partner GlaxoSmithKline
View HTML
Toggle Summary ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors Mountain View, CA - January 17, 2008 - ChemoCentryx, Inc. today announced the appointment of Edward E. Penhoet, Ph.D., to the company's Board of Directors. Dr. Penhoet is recognized for his 25 years of leadership and
View HTML
Toggle Summary ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
Characterization of Receptor's Central Role in Cancer is Published in the Proceedings of the National Academy of Sciences
View HTML
Toggle Summary ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for Nomination of CCR1 Small Molecule Development Candidate
ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for Nomination of CCR1 Small Molecule Development Candidate Mountain View, CA - July 24, 2007 - ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered
View HTML
Toggle Summary ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN™ in Crohn's Disease at the Digestive Disease Week 2007 Conference
Clear Anti-Inflammatory Activity Demonstrated Among Patients with Active Disease
View HTML
Toggle Summary ChemoCentryx's Traficet-EN™ Phase 2 Data in Crohn's Disease Accepted for Oral Presentation and Highlighted in "Best of UEGW" Session at DDW 2007
ChemoCentryx's Traficet-EN™ Phase 2 Data in Crohn's Disease Accepted for Oral Presentation and Highlighted in "Best of UEGW" Session at DDW 2007 Mountain View, CA - May 17, 2007 — ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing
View HTML
Toggle Summary ChemoCentryx Appoints Juan Jaen, Ph.D., Senior Vice President, Drug Discovery
ChemoCentryx Appoints Juan Jaen, Ph.D., Senior Vice President, Drug Discovery Mountain View, CA - January 4, 2007 — ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine
View HTML
Toggle Summary ChemoCentryx Presents Clinical and Preclinical Data on Traficet-EN® in Inflammatory Bowel Disease (IBD)
Clinical Analysis Shows that Traficet-EN Reduces Inflammation Associated with IBD
View HTML
Toggle Summary ChemoCentryx Reports Promising Clinical Activity for Traficet-EN™ from Phase 2 Trial for the Treatment of Crohn's Disease
Phase 2 Results Used in Design of Ongoing 400+ Patient PROTECT-1 Clinical Trial
View HTML